Developer docs
API playgroundTry for free, no card

Search company profiles

Alliance Pharmaceuticals

Full company profile

uuid002ge6v

Namestring
Alliance Pharmaceuticals
Legal namestring
Alliance Pharmaceuticals Limited
Company typeenum
Private
Founded yearint
1996
Descriptiontext

Alliance Pharmaceuticals is a UK-headquartered international consumer healthcare business that acquires, licenses, and markets a portfolio of clinically validated over-the-counter brands across dermatology, eye health, anti-dandruff, women's health, baby care, and oral care. Since January 2026, following the divestiture of its pharmaceutical division, the company has operated exclusively as a consumer healthcare business. The brand portfolio comprises Kelo-Cote (a patent-protected silicone gel scar treatment sold in 65+ countries, supported by over 10 published clinical trials), MacuShield (the UK's number-one eye supplement recommended by eye experts, with a proprietary LMZ3 blend of lutein, meso-zeaxanthin, and zeaxanthin), Nizoral (medicated anti-dandruff shampoo in 14 APAC territories, marketed as Triatop in China), Amberen (US-marketed non-hormonal menopause supplement), Vamousse (pesticide-free physical-mode lice treatment), Hydromol (eczema/dry skin emollient therapy), Forceval (multivitamins and trace elements), Ashton & Parsons (UK's number-one teething brand since 1867), Anbesol (oral pain relief), and Aloclair (mouth ulcer treatment).

The business generates revenue through two streams. The primary stream is direct product sales via retail pharmacy (Boots in the UK, with 60% post-campaign growth in Kelo-Cote sales), regional e-commerce (Tmall in China, generating £3.0m from 144,000 units during Singles' Day 2023), HCP endorsements (plastic surgeons, dermatologists, GPs, pharmacists, and nurses), and international distributors spanning more than 65 countries. The secondary stream is brand licensing royalties — Nizoral rights are licensed to STADA in EMEA and to Kramer in the USA, while Alliance retains APAC rights. Operations are asset-light, with manufacturing outsourced to third-party GMP-certified contract manufacturers, allowing capital to be directed at brand investment, HCP engagement, and channel marketing.

Ownership and corporate structure have shifted significantly: Alliance Pharma PLC was acquired by DBAY Partners on 14 May 2025 and delisted from the AIM market of the London Stock Exchange, becoming Alliance Pharma Ltd. Under private ownership, the company executed a strategic review and divested its pharmaceutical division to two UK acquirers on 7 January 2026. Headcount totals approximately 290 people across nine locations in the UK (Chippenham HQ), Germany (Düsseldorf DACH), China (Shanghai, with Production Approval Certificate), Singapore, Thailand, the Philippines, the United States (Cary, NC), and France. Headcount disclosures show 59% female workforce, 41% male, with 36% female representation in senior management in 2023. The company also maintains UN Global Compact membership (joined August 2024) and a Great Place to Work Trust Index engagement score of 74%.

Short descriptiontext

Alliance Pharmaceuticals is a UK-headquartered consumer healthcare business marketing clinically validated OTC brands across dermatology, eye health, anti-dandruff, women's health, baby care, and oral care. Following its May 2025 acquisition by DBAY Partners and January 2026 divestiture of its pharma division, it operates as a private consumer health pure-play distributing brands such as Kelo-Cote, MacuShield, Nizoral, Amberen, Hydromol, and Ashton & Parsons across 65+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersChippenham, United Kingdom
HQ citystring
Chippenham
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
consumer healthcare products, scar treatment gels, dermatology products, nutritional supplements, over-the-counter medicines
Industry3 codes
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Health and Personal Care Retailers456
  • Food (Health) Supplement Retailers456191
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Consumer Healthcare Products
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Consumer Healthcare Product Sales
TypeOne Time License
Description

Alliance Pharma generates revenue through the sale of consumer healthcare products including scar treatments (Kelo-Cote), anti-dandruff shampoo (Nizoral in APAC), eye health supplements (MacuShield), menopause supplements (Amberen), lice treatments (Vamousse), eczema treatments (Hydromol), multivitamins (Forceval), teething products (Ashton & Parsons), oral pain relief (Anbesol), and mouth ulcer treatments (Aloclair). Products are sold across multiple geographies including UK, Europe, Asia Pacific, and USA.

alliancepharmaceuticals.com
2International Brand Licensing
TypeLicensing Royalties
Description

The company licenses its brands internationally - for example, Nizoral brand rights are licensed to STADA for EMEA region and to Kramer for USA, while Alliance holds rights for APAC territories.

alliancepharmaceuticals.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Marketing or Sales, Personnel, Operations, Technology or R&D, Others
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 10 records shown
1KELO-COTE
Description

Advanced formula silicone gel treatment for scar reduction, sold in more than 65 countries. Clinically proven for treatment and prevention of hypertrophic and keloid scars.

alliancepharmaceuticals.com
+9 more records
Core offering1 text field

Alliance Pharmaceuticals acquires, licenses, and markets a portfolio of consumer healthcare brands sold across more than 65 countries. Its products span scar treatment (Kelo-Cote), anti-dandruff shampoo (Nizoral in APAC), eye health supplements (MacuShield), menopause supplements (Amberen), head lice treatment (Vamousse), eczema emollients (Hydromol), multivitamins (Forceval), teething products (Ashton & Parsons), oral pain relief (Anbesol), and mouth ulcer treatments (Aloclair). Following the January 2026 divestiture of its pharmaceutical division, the company is exclusively focused on consumer health brands.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 60% sales increase at Boots following UK billboard campaign for Kelo-Cote
+5 more records
Product overview1 text field

Alliance Pharmaceuticals is a leading international consumer healthcare business operating as a unified portfolio of consumer healthcare brands. The company specializes in advanced skincare solutions (including Kelo-Cote™ scar treatment, Hydromol™ for eczema) and vitamins, minerals & supplements (including MacuShield™ eye health, Amberen™ menopause relief, Forceval™ multivitamins). Additional brands include Nizoral™ anti-dandruff shampoo, Vamousse™ head lice treatment, Ashton & Parsons™ teething products, Anbesol™ oral pain relief, and Aloclair™ mouth sore treatment. Products are distributed internationally across multiple geographies including UK, Europe, Asia Pacific, and North America through retail, e-commerce, healthcare providers, and distributors.

Product and service10 records
1Kelo-Cote
CategoryConsumer Healthcare Product
Description

Patent-protected, clinically proven silicone gel treatment for scar reduction and prevention, sold in more than 65 countries. Intended for treatment and prevention of hypertrophic and keloid scars from surgical procedures, trauma, wounds and burns.

2Nizoral
CategoryConsumer Healthcare Product
Description

Medicated anti-dandruff shampoo that kills the fungus causing itchy, flaky scalps and dandruff. Sold in 14 territories across Asia Pacific including China, Japan, Thailand and Korea; marketed as Triatop in China. Alliance holds rights for APAC territories.

3Amberen
CategoryConsumer Healthcare Product
Description

Clinically evidenced range of over-the-counter supplement products marketed in the USA for relief of menopause and perimenopause symptoms. Non-hormonal dietary supplement comprising proprietary formulation of bioactive antioxidants (succinates), amino acids, minerals and Vitamin E.

4MacuShield
CategoryConsumer Healthcare Product
Description

Eye supplement brand featuring MacuShield Original with LMZ3, a proprietary blend of all three macular carotenoids (lutein, meso-zeaxanthin and zeaxanthin) derived from marigold flower. Number one recommended supplement by eye experts in the UK.

5Vamousse
CategoryConsumer Healthcare Product
Description

Range of pesticide-free products for prevention and treatment of head lice and nits. Lead product uses a physical mode of action that kills both lice and eggs and is effective against pesticide-resistant 'super lice'.

6Hydromol
CategoryConsumer Healthcare Product
Description

Range of products for treatment and management of eczema and dry skin conditions. Products contain emollients that form protective barriers on skin and can be used individually or together as a Complete Emollient Therapy regime.

7Forceval
CategoryConsumer Healthcare Product
Description

Range of nutritional support products including Forceval Capsules (medicinal multivitamin containing 24 vitamins, minerals and trace elements), Forceval Soluble, and Forceval Soluble Junior effervescent tablets.

8Ashton & Parsons
CategoryConsumer Healthcare Product
Description

UK's No 1 Teething brand since 1867. Includes Ashton & Parsons Teething Powders (traditional herbal medicinal product) and Teething Gel (medical device). Products are local anaesthetic-free, lactose-free, sugar-free and alcohol-free.

9Anbesol
CategoryConsumer Healthcare Product
Description

Range of oral pain relief products for the family covering mouth ulcers, denture irritation, and teething. Includes Adult Strength Gel (12+ years), Liquid, and Teething Gel, with formulations including Lidocaine and antiseptics.

10Aloclair
CategoryConsumer Healthcare Product
Description

Products for sore mouth relief containing PVP and Sodium Hyaluronate with Aloe Vera. Offers long lasting pain relief and promotes fast healing with gel, mouthwash or spray formulations for age ranges from 3 months to adult.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
1Two Unrelated UK Pharmaceutical Companies
Strategic tierMajorTypeOthersAnnounced on2026-01-07
Description

Alliance Pharmaceuticals Limited entered into a definitive agreement to sell its pharmaceutical division to two unrelated UK pharmaceutical companies. The transaction completed on 7th January 2026 following a comprehensive strategic review aligned with Alliance's strategy to become a leading consumer health business.

alliancepharmaceuticals.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-08-01
Description

Alliance continued its participation as a member of the UN Global Compact, officially joining in August 2024. First Communication on Progress (COP) submitted in July 2025.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Three-year partnership with Slave-Free Alliance, a social enterprise wholly owned by global anti-slavery charity Hope for Justice, to increase resilience to modern slavery and labour exploitation in operations and supply chains. Alliance worked with SFA to carry out gap analysis, strengthened Modern Slavery Statement, and provided training to quality and sourcing chain teams.

Strategic tierMinorTypeOthers
Description

Product donations to International Health Partners, a global health NGO, supporting people in disaster-hit and vulnerable communities to get vital medicines. Donated 17,000 products to support 47,000 patients in 14 countries around the world.

Strategic tierMinorTypeOthers
Description

Charitable partnership with SmileTrain as part of Alliance's social impact initiatives.

6SANDS (UK)
Strategic tierMinorTypeOthers
Description

Charitable partnership with SANDS (UK) supporting baby loss awareness and related causes.

alliancepharmaceuticals.com
Strategic tierMinorTypeOthers
Description

Local charity partnership with The Hygiene Bank for collections of essential hygiene items.

8Julian House
Strategic tierMinorTypeOthers
Description

Local charity partnership with Julian House for support of homeless individuals.

alliancepharmaceuticals.com
Strategic tierMinorTypeOthers
Description

Independent third-party helpline enabling employees, partners, and the public to report concerns anonymously (including modern slavery concerns) from over 100 countries, operational 24/7 in over 60 languages.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

STADA acquired EMEA rights to Nizoral anti-dandruff brand from Johnson & Johnson. Alliance previously held APAC rights.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Krama Healthcare holds rights to Nizoral in the USA market.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

European dermatology-focused specialty pharma company with a mix of prescription and OTC/consumer dermatology brands. Comparable to Alliance's dermatology-led, Europe-anchored consumer health positioning.

TypeDirect peer
Description

Global OTC consumer healthcare and self-care products company with extensive dermatology, oral care, and women's health franchises. Comparable as a diversified OTC consumer health operator with global distribution.

TypeRegional player
Description

Asia-Pacific and emerging-market focused consumer healthcare and specialty pharma company with OTC, dermatology, and women's health brands. Comparable as a regional consumer health operator focused on APAC distribution, mirroring Alliance's APAC affiliate footprint.

TypeDirect peer
Description

Pure-play dermatology specialty company covering prescription aesthetics, therapeutic dermatology, and consumer skincare. Direct comparable in the dermatology category where Kelo-Cote and Hydromol compete.

TypeDirect peer
Description

US-listed specialty consumer healthcare company that acquires, licenses, and markets established OTC healthcare brands across categories (GI, dermatology, eye care, women's health). Closely comparable to Alliance's acquire-and-grow model and brand portfolio construction.

TypeEmerging player
Description

Consumer products company with personal care and OTC-adjacent brands (Batiste, First Response, Waterpik). Compares as a branded consumer health/personal-care operator with selective OTC extensions.

7Bayer Consumer Health
TypeBroad incumbent
Description

Large incumbent OTC consumer health division within Bayer with dermatology, women's health, and supplement brands (e.g., Canesten, Elevit). Overlaps with Alliance's Kelo-Cote, Hydromol, and Amberen-adjacent categories.

TypeBroad incumbent
Description

Global consumer health major with brands such as Nurofen, Strepsils, Gaviscon, and Dettol. Competes with Alliance across OTC self-care categories, including oral pain (Anbesol) and dermatology (Hydromol).

TypeDirect peer
Description

European-headquartered generics and consumer healthcare company with a portfolio of OTC brands, including Nizoral EMEA. Highly comparable to Alliance's European consumer health model and is a direct counterparty in Alliance's licensing structure.

TypeBroad incumbent
Description

Global consumer healthcare leader (spun out of GSK) with major OTC brands across oral care, pain, vitamins, and skin health. Overlaps with Alliance across OTC self-care categories but at vastly larger scale.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alliance Pharmaceuticals

Consumer Healthcare Productsalliancepharmaceuticals.com

Alliance Pharmaceuticals is a UK-headquartered consumer healthcare business marketing clinically validated OTC brands across dermatology, eye health, anti-dandruff, women's health, baby care, and oral care. Following its May 2025 acquisition by DBAY Partners and January 2026 divestiture of its pharma division, it operates as a private consumer health pure-play distributing brands such as Kelo-Cote, MacuShield, Nizoral, Amberen, Hydromol, and Ashton & Parsons across 65+ countries.

What Alliance Pharmaceuticals does

Alliance Pharmaceuticals is a UK-headquartered international consumer healthcare business that acquires, licenses, and markets a portfolio of clinically validated over-the-counter brands across dermatology, eye health, anti-dandruff, women's health, baby care, and oral care. Since January 2026, following the divestiture of its pharmaceutical division, the company has operated exclusively as a consumer healthcare business. The brand portfolio comprises Kelo-Cote (a patent-protected silicone gel scar treatment sold in 65+ countries, supported by over 10 published clinical trials), MacuShield (the UK's number-one eye supplement recommended by eye experts, with a proprietary LMZ3 blend of lutein, meso-zeaxanthin, and zeaxanthin), Nizoral (medicated anti-dandruff shampoo in 14 APAC territories, marketed as Triatop in China), Amberen (US-marketed non-hormonal menopause supplement), Vamousse (pesticide-free physical-mode lice treatment), Hydromol (eczema/dry skin emollient therapy), Forceval (multivitamins and trace elements), Ashton & Parsons (UK's number-one teething brand since 1867), Anbesol (oral pain relief), and Aloclair (mouth ulcer treatment).

The business generates revenue through two streams. The primary stream is direct product sales via retail pharmacy (Boots in the UK, with 60% post-campaign growth in Kelo-Cote sales), regional e-commerce (Tmall in China, generating £3.0m from 144,000 units during Singles' Day 2023), HCP endorsements (plastic surgeons, dermatologists, GPs, pharmacists, and nurses), and international distributors spanning more than 65 countries. The secondary stream is brand licensing royalties — Nizoral rights are licensed to STADA in EMEA and to Kramer in the USA, while Alliance retains APAC rights. Operations are asset-light, with manufacturing outsourced to third-party GMP-certified contract manufacturers, allowing capital to be directed at brand investment, HCP engagement, and channel marketing.

Ownership and corporate structure have shifted significantly: Alliance Pharma PLC was acquired by DBAY Partners on 14 May 2025 and delisted from the AIM market of the London Stock Exchange, becoming Alliance Pharma Ltd. Under private ownership, the company executed a strategic review and divested its pharmaceutical division to two UK acquirers on 7 January 2026. Headcount totals approximately 290 people across nine locations in the UK (Chippenham HQ), Germany (Düsseldorf DACH), China (Shanghai, with Production Approval Certificate), Singapore, Thailand, the Philippines, the United States (Cary, NC), and France. Headcount disclosures show 59% female workforce, 41% male, with 36% female representation in senior management in 2023. The company also maintains UN Global Compact membership (joined August 2024) and a Great Place to Work Trust Index engagement score of 74%.

Alliance Pharmaceuticals firmographics

Firmographics
Name
Alliance Pharmaceuticals
Legal name
Alliance Pharmaceuticals Limited
Website
https://alliancepharmaceuticals.com
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Alliance Pharmaceuticals is a UK-headquartered consumer healthcare business marketing clinically validated OTC brands across dermatology, eye health, anti-dandruff, women's health, baby care, and oral care. Following its May 2025 acquisition by DBAY Partners and January 2026 divestiture of its pharma division, it operates as a private consumer health pure-play distributing brands such as Kelo-Cote, MacuShield, Nizoral, Amberen, Hydromol, and Ashton & Parsons across 65+ countries.
Ownership category
akta.pro rank

Alliance Pharmaceuticals industry classification

Industry
Product category
Consumer Healthcare Products
NAICS
Pharmaceutical Preparation Manufacturing (325412), Health and Personal Care Retailers (456), Food (Health) Supplement Retailers (456191)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals

Keywords

  • Consumer healthcare products
  • Scar treatment gels
  • Dermatology products
  • Nutritional supplements
  • Over-the-counter medicines

Where Alliance Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Chippenham
HQ country
United Kingdom
HQ region
Europe

Offices8 records

Markets served

Alliance Pharmaceuticals business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Marketing or Sales, Personnel, Operations, Technology or R&D, Others

Revenue model

  1. Consumer Healthcare Product Sales: Alliance Pharma generates revenue through the sale of consumer healthcare products including scar treatments (Kelo-Cote), anti-dandruff shampoo (Nizoral in APAC), eye health supplements (MacuShield), menopause supplements (Amberen), lice treatments (Vamousse), eczema treatments (Hydromol), multivitamins (Forceval), teething products (Ashton & Parsons), oral pain relief (Anbesol), and mouth ulcer treatments (Aloclair). Products are sold across multiple geographies including UK, Europe, Asia Pacific, and USA.
  2. International Brand Licensing: The company licenses its brands internationally - for example, Nizoral brand rights are licensed to STADA for EMEA region and to Kramer for USA, while Alliance holds rights for APAC territories.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Alliance Pharmaceuticals product offering

Product offering

Core offering

Alliance Pharmaceuticals acquires, licenses, and markets a portfolio of consumer healthcare brands sold across more than 65 countries. Its products span scar treatment (Kelo-Cote), anti-dandruff shampoo (Nizoral in APAC), eye health supplements (MacuShield), menopause supplements (Amberen), head lice treatment (Vamousse), eczema emollients (Hydromol), multivitamins (Forceval), teething products (Ashton & Parsons), oral pain relief (Anbesol), and mouth ulcer treatments (Aloclair). Following the January 2026 divestiture of its pharmaceutical division, the company is exclusively focused on consumer health brands.

Product overview

Alliance Pharmaceuticals is a leading international consumer healthcare business operating as a unified portfolio of consumer healthcare brands. The company specializes in advanced skincare solutions (including Kelo-Cote™ scar treatment, Hydromol™ for eczema) and vitamins, minerals & supplements (including MacuShield™ eye health, Amberen™ menopause relief, Forceval™ multivitamins). Additional brands include Nizoral™ anti-dandruff shampoo, Vamousse™ head lice treatment, Ashton & Parsons™ teething products, Anbesol™ oral pain relief, and Aloclair™ mouth sore treatment. Products are distributed internationally across multiple geographies including UK, Europe, Asia Pacific, and North America through retail, e-commerce, healthcare providers, and distributors.

Differentiator

Problem solved

Functional benefit

Brands

  • KELO-COTE: Advanced formula silicone gel treatment for scar reduction, sold in more than 65 countries. Clinically proven for treatment and prevention of hypertrophic and keloid scars.
  • Nizoral
  • Amberen
  • MacuShield
  • Vamousse
  • Hydromol
  • Forceval
  • Ashton & Parsons
  • Anbesol
  • Aloclair

Products and services

  • Kelo-Cote Patent-protected, clinically proven silicone gel treatment for scar reduction and prevention, sold in more than 65 countries. Intended for treatment and prevention of hypertrophic and keloid scars from surgical procedures, trauma, wounds and burns.
  • Nizoral Medicated anti-dandruff shampoo that kills the fungus causing itchy, flaky scalps and dandruff. Sold in 14 territories across Asia Pacific including China, Japan, Thailand and Korea; marketed as Triatop in China. Alliance holds rights for APAC territories.
  • Amberen Clinically evidenced range of over-the-counter supplement products marketed in the USA for relief of menopause and perimenopause symptoms. Non-hormonal dietary supplement comprising proprietary formulation of bioactive antioxidants (succinates), amino acids, minerals and Vitamin E.
  • MacuShield Eye supplement brand featuring MacuShield Original with LMZ3, a proprietary blend of all three macular carotenoids (lutein, meso-zeaxanthin and zeaxanthin) derived from marigold flower. Number one recommended supplement by eye experts in the UK.
  • Vamousse Range of pesticide-free products for prevention and treatment of head lice and nits. Lead product uses a physical mode of action that kills both lice and eggs and is effective against pesticide-resistant 'super lice'.
  • Hydromol Range of products for treatment and management of eczema and dry skin conditions. Products contain emollients that form protective barriers on skin and can be used individually or together as a Complete Emollient Therapy regime.
  • Forceval Range of nutritional support products including Forceval Capsules (medicinal multivitamin containing 24 vitamins, minerals and trace elements), Forceval Soluble, and Forceval Soluble Junior effervescent tablets.
  • Ashton & Parsons UK's No 1 Teething brand since 1867. Includes Ashton & Parsons Teething Powders (traditional herbal medicinal product) and Teething Gel (medical device). Products are local anaesthetic-free, lactose-free, sugar-free and alcohol-free.
  • Anbesol Range of oral pain relief products for the family covering mouth ulcers, denture irritation, and teething. Includes Adult Strength Gel (12+ years), Liquid, and Teething Gel, with formulations including Lidocaine and antiseptics.
  • Aloclair Products for sore mouth relief containing PVP and Sodium Hyaluronate with Aloe Vera. Offers long lasting pain relief and promotes fast healing with gel, mouthwash or spray formulations for age ranges from 3 months to adult.

Quantifiable outcome

  • 60% sales increase at Boots following UK billboard campaign for Kelo-Cote
  • +5 more outcomes

Companies that use Alliance Pharmaceuticals

Customer profile

Named customers3 records

Segments7 records

Ideal customer profiles3 records

Alliance Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Alliance Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered major, core and minor.

  • Two Unrelated UK Pharmaceutical CompaniesmajorOthers · 7 January 2026Alliance Pharmaceuticals Limited entered into a definitive agreement to sell its pharmaceutical division to two unrelated UK pharmaceutical companies. The transaction completed on 7th January 2026 following a comprehensive strategic review aligned with Alliance's strategy to become a leading consumer health business.
  • UN Global CompactcoreStrategic or Co-development Partner · 1 August 2024Alliance continued its participation as a member of the UN Global Compact, officially joining in August 2024. First Communication on Progress (COP) submitted in July 2025.
  • Slave-Free AlliancecoreStrategic or Co-development Partner · 1 January 2022Three-year partnership with Slave-Free Alliance, a social enterprise wholly owned by global anti-slavery charity Hope for Justice, to increase resilience to modern slavery and labour exploitation in operations and supply chains. Alliance worked with SFA to carry out gap analysis, strengthened Modern Slavery Statement, and provided training to quality and sourcing chain teams.
  • International Health PartnersminorOthersProduct donations to International Health Partners, a global health NGO, supporting people in disaster-hit and vulnerable communities to get vital medicines. Donated 17,000 products to support 47,000 patients in 14 countries around the world.
  • SmileTrainminorOthersCharitable partnership with SmileTrain as part of Alliance's social impact initiatives.
  • SANDS (UK)minorOthersCharitable partnership with SANDS (UK) supporting baby loss awareness and related causes.
  • The Hygiene BankminorOthersLocal charity partnership with The Hygiene Bank for collections of essential hygiene items.
  • Julian HouseminorOthersLocal charity partnership with Julian House for support of homeless individuals.
  • SafecallminorOthersIndependent third-party helpline enabling employees, partners, and the public to report concerns anonymously (including modern slavery concerns) from over 100 countries, operational 24/7 in over 60 languages.
  • STADAmajorChannel Partner/ Reseller/ DistributorSTADA acquired EMEA rights to Nizoral anti-dandruff brand from Johnson & Johnson. Alliance previously held APAC rights.
  • KramermajorChannel Partner/ Reseller/ DistributorKrama Healthcare holds rights to Nizoral in the USA market.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Alliance Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Almirall: European dermatology-focused specialty pharma company with a mix of prescription and OTC/consumer dermatology brands. Comparable to Alliance's dermatology-led, Europe-anchored consumer health positioning.
  • Perrigo Company: Global OTC consumer healthcare and self-care products company with extensive dermatology, oral care, and women's health franchises. Comparable as a diversified OTC consumer health operator with global distribution.
  • Galderma: Pure-play dermatology specialty company covering prescription aesthetics, therapeutic dermatology, and consumer skincare. Direct comparable in the dermatology category where Kelo-Cote and Hydromol compete.
  • Prestige Consumer Healthcare: US-listed specialty consumer healthcare company that acquires, licenses, and markets established OTC healthcare brands across categories (GI, dermatology, eye care, women's health). Closely comparable to Alliance's acquire-and-grow model and brand portfolio construction.
  • STADA Arzneimittel: European-headquartered generics and consumer healthcare company with a portfolio of OTC brands, including Nizoral EMEA. Highly comparable to Alliance's European consumer health model and is a direct counterparty in Alliance's licensing structure.

Regional players

  • iNova Pharmaceuticals: Asia-Pacific and emerging-market focused consumer healthcare and specialty pharma company with OTC, dermatology, and women's health brands. Comparable as a regional consumer health operator focused on APAC distribution, mirroring Alliance's APAC affiliate footprint.

Emerging players

  • Church & Dwight: Consumer products company with personal care and OTC-adjacent brands (Batiste, First Response, Waterpik). Compares as a branded consumer health/personal-care operator with selective OTC extensions.

Broad incumbents

  • Bayer Consumer Health: Large incumbent OTC consumer health division within Bayer with dermatology, women's health, and supplement brands (e.g., Canesten, Elevit). Overlaps with Alliance's Kelo-Cote, Hydromol, and Amberen-adjacent categories.
  • Reckitt Benckiser (Health): Global consumer health major with brands such as Nurofen, Strepsils, Gaviscon, and Dettol. Competes with Alliance across OTC self-care categories, including oral pain (Anbesol) and dermatology (Hydromol).
  • Haleon: Global consumer healthcare leader (spun out of GSK) with major OTC brands across oral care, pain, vitamins, and skin health. Overlaps with Alliance across OTC self-care categories but at vastly larger scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Alliance Pharmaceuticals social profiles

Digital presence

Alliance Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alliance Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles2 records

Alliance Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alliance Pharmaceuticals M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alliance Pharmaceuticals

What does Alliance Pharmaceuticals do?

Alliance Pharmaceuticals acquires, licenses, and markets a portfolio of consumer healthcare brands sold across more than 65 countries. Its products span scar treatment (Kelo-Cote), anti-dandruff shampoo (Nizoral in APAC), eye health supplements (MacuShield), menopause supplements (Amberen), head lice treatment (Vamousse), eczema emollients (Hydromol), multivitamins (Forceval), teething products (Ashton & Parsons), oral pain relief (Anbesol), and mouth ulcer treatments (Aloclair). Following the January 2026 divestiture of its pharmaceutical division, the company is exclusively focused on consumer health brands.

Is Alliance Pharmaceuticals a public or private company?

Alliance Pharmaceuticals is a private company. It is classified as private equity controlled and is currently operating.

When was Alliance Pharmaceuticals founded?

Alliance Pharmaceuticals was founded in 1996. It employs 501 to 1,000 people.

Where is Alliance Pharmaceuticals based?

Alliance Pharmaceuticals is headquartered in Chippenham, United Kingdom, in the Europe region.

How does Alliance Pharmaceuticals make money?

Two revenue lines are on record. Consumer Healthcare Product Sales are the primary driver. The others are international Brand Licensing.

Who are Alliance Pharmaceuticals's main competitors?

Direct peers on record are Almirall, Perrigo Company, Galderma, Prestige Consumer Healthcare and STADA Arzneimittel. iNova Pharmaceuticals is listed as a regional player. Church & Dwight is listed as an emerging player. Broad incumbents are Bayer Consumer Health, Reckitt Benckiser (Health) and Haleon.

Does Alliance Pharmaceuticals have an API?

No public API is recorded for Alliance Pharmaceuticals.

What industry is Alliance Pharmaceuticals in?

Alliance Pharmaceuticals's product category is Consumer Healthcare Products. Its primary akta.pro industry code is HLAIACAL, Dermatology Specialty Pharmaceuticals, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StUK Domestic Pharmaceutical Manufacturers Three Stocks With Hidden UpsideSimply Wall St has identified three UK pharmaceutical manufacturers—hVIVO, Alliance Pharma, and Oxford Biomedica—as potential investment opportunities amid NHS medicine shortages and increasing pressure on pharmacy supply chains. hVIVO generates £49.66m in revenue from contract clinical trials and has a market cap of £54.27m, Alliance Pharma produces £178.83m from consumer healthcare and prescription products with a £350.27m market cap, and Oxford Biomedica earns £168.74m from viral vector manufacturing for cell and gene therapies with a £737.62m market cap. All three companies are currently loss-making, with analysts highlighting UK domestic manufacturing capacity and supply resilience as potential catalysts if NHS shortages persist and drive demand for local production capability.HalifaxHalifax – Market newsDBAY Advisors has agreed to acquire AIM-listed Alliance Pharma in a £349.7 million cash deal, offering a 40.9% premium over the previous closing share price. As Alliance's largest shareholder with a 27.9% stake, DBAY aims to provide operational expertise and capital to accelerate the company's growth strategy through innovation and expansion.CB InsightsProducts, Competitors, Financials, Employees, Headquarters LocationsTrueMed, a Helsinki-based AI counterfeit detection provider, announced a strategic collaboration with U.S.-based Alliance Pharmaceuticals Ltd to protect medicines and healthcare products from sophisticated counterfeits using digital authentication technology. The partnership enables Alliance to scan product images, generate instant evidence reports, and monitor markets in real-time, reportedly reducing counterfeit prevalence from 50% to under 5% across targeted product lines. The collaboration represents a shift from reactive to proactive brand protection leveraging AI-powered tools to identify and respond to counterfeiting threats within hours.ReutersUK's Alliance Pharma accepts DBAY's sweetened final offerUK-based Alliance Pharma has accepted a revised, sweetened final cash offer from asset management firm DBAY Advisors, valuing the healthcare group at approximately 362 million pounds. The new proposal of 64.75 pence per share represents a 3.6% increase over the previous bid and includes a 46% premium to Alliance's stock price before the offer period began. This agreement follows the adjournment of a general meeting in February that had delayed shareholder consideration of the initial deal.YahooAlliance Pharma agrees to £362m acquisition by DBAYUK-based Alliance Pharma has agreed to a final increased cash offer from asset management company DBAY Advisors, valuing the acquisition at approximately £362 million. The deal involves DBAY acquiring all remaining shares in Alliance for 64.75p per share, representing a 46% premium on the pre-offer share price, with shareholders set to vote on the proposal on 13 March 2025. If approved, Alliance Pharma will become a privately owned company under DBAY's control in the first half of 2025.ReutersLondon’s withering AIM market set to lose more members this yearLondon's AIM market is expected to lose more members in 2025 as UK fund outflows and tax changes make listings less attractive. 89 companies left the exchange last year, with 18 joining, and Alliance Pharma agreed to a takeover. Analysts warn AIM's disappearance would be catastrophic for UK startups.ReutersAsset management firm DBAY to buy UK's Alliance Pharma in $430 million dealDBAY Advisors agreed to acquire UK healthcare firm Alliance Pharma in an all-cash deal valued at 349.7 million pounds ($429.6 million). The 62.5 pence-per-share offer is a 41% premium to Thursday's close, with completion expected in the first half of 2025.LseDBAY Advisors to buy Alliance Pharma in £349.7m dealAIM-listed Alliance Pharma has agreed to be acquired by asset management firm DBAY Advisors in a £349.7m cash deal, offering shareholders a 62.5p per share price that represents a 40.9% premium. DBAY, which already holds a 27.9% stake in the company, cited the need for additional capital and operational expertise to accelerate Alliance's growth strategy amidst execution risks associated with its current public market status. The acquisition marks another departure of a profitable business from London's AIM market.UK Investor MagazineAlliance Pharma acquires ScarAway and US rights for Kelo-coteAlliance Pharma acquired ScarAway and US rights for Kelo-cote, paying $19.4m in cash and debt. ScarAway generated $10m in net sales from 2021-2022, and the deal is expected to boost profitability immediately.UK Investor MagazineAlliance Pharma sees pre-tax profit surge 39%Alliance Pharma reported pre-tax profits rose 39% to £18.2m in 2021, driven by e-commerce growth. Revenue increased 26% to £169.6m, with consumer healthcare up 31% and prescription medicine up 8%. The company also reduced net debt and increased dividends by 5%.